Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections
Stock Information for Spero Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.